A detailed history of Almitas Capital LLC transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Almitas Capital LLC holds 2,482,606 shares of LYEL stock, worth $22.7 Million. This represents 0.76% of its overall portfolio holdings.

Number of Shares
2,482,606
Previous 1,050,520 136.32%
Holding current value
$22.7 Million
Previous $672,000 99.4%
% of portfolio
0.76%
Previous 0.33%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 15, 2025

BUY
$0.48 - $0.74 $687,401 - $1.06 Million
1,432,086 Added 136.32%
2,482,606 $1.34 Million
Q4 2024

Feb 14, 2025

BUY
$0.59 - $1.48 $619,806 - $1.55 Million
1,050,520 New
1,050,520 $672,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $2.27B
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Almitas Capital LLC Portfolio

Follow Almitas Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Almitas Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Almitas Capital LLC with notifications on news.